Table 1 Descriptive statistics of risk factors associated with cardiotoxicity present in our study population
Descriptive Risk Factors of Incidence of Cardiotoxicity within the overall population | |||
|---|---|---|---|
Overall | No | Yes | |
n | 132 | 124 | 8 |
Age at diagnosis (mean) (SD) | 54.24 (13.02) | 54.11 (13.12) | 56.25 (12.12) |
Premature Discontinuation of Trastuzumab (%) | 17 (13) | 16 (13) | 1 (12.5) |
Baseline LVEF (mean) (SD) | 62.87 (4.56) | 62.91 (4.60) | 62.23 (4.16) |
BMI (mean) (SD) | 30.89 (7.81) | 30.97 (7.70) | 29.69 (9.77) |
Hx of PCI (%) | 2 (1.5) | 2 (1.6) | 0 (0.0) |
Hx of CAD (%) | 2 (1.5) | 1 (0.8) | 1 (12.5) |
Hx of Radiation Therapy (%) | 40 (30.8) | 39 (32) | 1 (12.5) |
Hx of Anthracycline Therapy (%) | 15 (11.6) | 13 (10.7) | 2 (25) |
Positive ER receptor status (%) | 83 (62.9) | 79 (63.7) | 4 (50.0) |
Positive PR receptor status (%) | 61 (46.2) | 58 (46.8) | 3 (37.5) |
HTN (%) | 67 (50.8) | 63 (50.8) | 4 (50.0) |
HLD (%) | 39 (30.5) | 37 (30.8) | 2 (25) |
CKD (%) | 9 (6.9) | 9 (7.4) | 0 (0.0) |
DM2 (%) | 29 (22.3) | 28 (23) | 1 (12.5) |
Number of TTEs (mean) (SD) | 3.54 (1.09) | 3.47 (1.08) | 4.62 (0.52) |
Race | |||
Black/African American | 9 (6.9) | 8 (6.6) | 1 (12.5) |
Caucasian | 115 (88.5) | 108 (88.5) | 7 (87.5) |
Other | 6 (4.6) | 6 (4.9) | 0 (0.0) |
Hispanic/Latino Ethnicity (%) | 77 (58.3) | 73 (58.9) | 4 (50) |
Previous smoker (%) | 31 (23.7) | 28 (22.8) | 3 (37.5) |
Previous alcohol use (%) | 41 (31.8) | 39 (32.2) | 2 (25) |